Q&A with Babu Padmanabhan, STEER Engineering - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Babu Padmanabhan, STEER Engineering
A Q&A with Babu Padmanabhan, Managing Director and Chief Knowledge Officer of STEER Engineering, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 8, pp. 71



Q&A with
Babu Padmanabhan, Managing Director and Chief Knowledge Officer of STEER Engineering

PharmTech:
How has the increasing focus on biopharmaceuticals affected your business?

Padmanabhan:
Our organization supports the bio/pharmaceutical industry by improving the effectiveness of the oral, skin, and intramuscular drug-delivery systems. We build the tools for engineering sustained and controlled release of drugs, enhanced bioavailability, drug-eluting stents, and implant-based, innovative drug-release systems. These methods are recent developments and have potential in both small-molecule drugs and biopharmaceuticals.

PharmTech:
How is your company responding to regulators' intensifying emphasis on inspections and product quality?

Padmanabhan:
Because we build tools for developing and manufacturing drug products, our equipment is built with full range of instrumentation and analytical systems that are compliant with current global regulatory requirements. We provide support in meeting the requirements of the design-, installation-, operational-, and performance-qualification protocols of various companies. Because of our exposure to many such protocols, our support to companies move them towards a better set of requirements (i.e., exceeding current requirements and preparing for the future).

PharmTech:
Do you see a new industry trend emerging?

Padmanabhan:
Continuous manufacturing is gaining significant attention among the pharmaceutical industry. Life-cycle management of existing drugs has been one of the current areas of focus. There is growing interest in equipment that supports the manufacturing of potent compounds with containment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
10%
Regulatory compliance
33%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here